A 34-year-old Hispanic man with HIV infection on no treatment (CD4 20/µL, viral load 1.9/10⁶ copies/mL) presented with 4 months of dizziness, ataxia, and scanning speech consistent with a pancerebellar syndrome. MRI scan (Figure) demonstrated marked cerebellar atrophy. CSF showed normal cell count, protein, and glucose levels, nonreactive venereal disease research laboratory test. CSF PCR was negative for cytomegalovirus, varicella-zoster, herpes simplex type 1 and 2, Epstein-Barr, and herpes virus 6, but positive for John Cunningham (JC) virus. JC virus granule cell neuronopathy (GCN) was diagnosed. JC virus variants may rarely infect cerebellar granule neurons instead of oligodendrocytes as seen in classic progressive multifocal leukoencephalopathy with white matter involvement.¹⁻² HAART (zidovudine, lamivudine, and efavirenz) commenced immediately, with slight symptomatic improvement at 12 months, MRI scan was unchanged. Clinicians should suspect JC virus strain infection producing GCN in AIDS patients with symptomatic cerebellar atrophy² and commence HAART promptly—immune reconstitution inflammatory syndrome is not usually a concern in cases of isolated JC virus GCN.

Author Contributions
C. Silva-Rosas: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data. G. Abudín: study concept or design; analysis or interpretation of data. A. Quijada-Riquelme: study concept or design; analysis or interpretation of data. H. Angus-Leppan: study concept or design; analysis or interpretation of data.

*These authors contributed equally to this work.

From the Department of Neurology & Neurosurgery (C.-R., G.A., A.Q.-R.), Clinical Hospital of University of Chile, Santiago de Chile; Royal Free London NHS Foundation Trust (H.A.-L.); and Department of Clinical and Movement Neurosciences (H.A.-L.), UCL Queen Square Institute of Neurology, United Kingdom.

Correspondence
Dr. Silva-Rosas
csilros@uchile.cl

Correspondence
Dr. Silva-Rosas
csilros@uchile.cl
Study Funding
No targeted funding reported.

Disclosure
The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

Publication History
Received by Neurology October 19, 2022. Accepted in final form January 20, 2023. Submitted and externally peer reviewed. The handling editor was Resident and Fellow Section Editor Whitley Aamodt, MD, MPH.

Appendix Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carlos Silva-Rosas, MD</td>
<td>Department of Neurology &amp; Neurosurgery, Clinical Hospital of University of Chile, Santiago de Chile</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data</td>
</tr>
<tr>
<td>Gabriel Abudinén, MD</td>
<td>Department of Neurology &amp; Neurosurgery, Clinical Hospital of University of Chile, Santiago de Chile</td>
<td>Study concept or design and analysis or interpretation of data</td>
</tr>
<tr>
<td>Alonso Quijada-Riquelme, MD</td>
<td>Department of Neurology &amp; Neurosurgery, Clinical Hospital of University of Chile, Santiago de Chile</td>
<td>Study concept or design and analysis or interpretation of data</td>
</tr>
<tr>
<td>Heather Angus-Leppan, MBBS (Hons), MSc, MD, FRACP, FRCP</td>
<td>Royal Free London NHS Foundation Trust; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, United Kingdom</td>
<td>Study concept or design and analysis or interpretation of data</td>
</tr>
</tbody>
</table>

References